h a medicine that contains a sulfonylurea,
hypoglycemia (low blood sugar) is a possible side effect. To reduce this
possibility, the dose of sulfonylurea medicine may need to be reduced while
using BYETTA. Other common side effects with BYETTA include nausea, vomiting,
diarrhea, dizziness, headache, feeling jittery, and acid stomach. Nausea is
the most common side effect when first starting BYETTA, but decreases over
time in most patients.
If patients experience the following severe and persistent symptoms (alone
or in combination): abdominal pain, nausea, vomiting, or diarrhea, they should
talk to their healthcare provider because these symptoms could be signs of
serious medical conditions. BYETTA may reduce appetite, the amount of food
eaten, and body weight. No changes in dose are needed for these side effects.
These are not all of the side effects from use of BYETTA. A healthcare
provider should be consulted about any side effect that is bothersome or does
not go away.
For full prescribing information, visit www.BYETTA.com.
About Amylin, Lilly and Alkermes
Amylin, Lilly, and Alkermes are working together to develop exenatide once
weekly, a subcutaneous injection of exenatide for the treatment of type 2
diabetes based on Alkermes' proprietary technology for long-acting
medications. Exenatide once weekly is not currently approved by any regulatory
Amylin Pharmaceuticals is a biopharmaceutical company committed to
improving lives through the discovery, development and commercialization of
innovative medicines. Amylin's research and development activities leverage
the company's expertise in metabolism to develop potential therapies to treat
diabetes and obesity. Amylin is headquartered in San Diego, California.
Through a long-standing commitment to diabetes care, Lilly provides
patients with breakthrougPage: 1 2 3 4 5 6 7 Related medicine technology :1
. Bionovo Announces Development Plans for Menopausal Hot Flash Drug Candidate, Menerba (MF101), Following FDA Meetings2
. Wound Management Technologies, Inc. Announces Conference Plans in Boston and Additional Clinical Research on CellerateRx(R)3
. Epiphany Biosciences to Continue Phase 2 Shingles Study After Interim Analysis; Plans Follow-On Clinical Trial Studying Post-Herpetic Neuralgia (PHN)4
. CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study5
. GlaxoSmithKline Responds to FDA on CERVARIX(R) and Plans to Submit Final Study Data for Approval6
. Repligen Announces Plans to Initiate a Phase 2b Trial for RG2417 in Bipolar Disorder7
. Quigley Announces Successful Poultry Study of Chickens With Infectious Bronchitis; Plans to Approach the Poultry Industry for Potential Commercialization8
. Clinsys(R) TPS Teams Provide Comprehensive Clinical Development Plans9
. Biodel Inc. Completes Enrollment of Two Pivotal Phase III Clinical Trials of VIAject(TM) and Plans Manufacturing Facility for VIAject(TM)10
. IDM Pharma Provides Update of Product Pipeline and Announces Plans to Evaluate Strategic Alternatives for the Company11
. Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease